A study of tremor classification in Parkinson's disease based on drug responsiveness

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050984

Enrollment

Unknown

Registered

2021-09-09

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

Group 1:dopaminergic drugs

Group 2:anticholinergic drugs

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 50-85 years; 2. Patients with primary Parkinson's disease; 3. MDS-UPDRS III resting tremor single score >=1 point, and at least one upper limb has resting tremor.

Exclusion criteria

Exclusion criteria: 1. Have neurological comorbidities; 2. Psychogenic tremor; 3. Known allergy to levodopa-benserazide or mosapride; 4. Glaucoma, benign prostatic hyperplasia, urinary retention; 5. Cognitive impairment (MMSE < 24 or FAB < 12 points).

Design outcomes

Primary

Measure	Time frame
Parkinson's composite rating scale version 3.0 score;Fahn-Tolosa-Marin tremor rating scale;EMG tremor analysis;	—

Secondary

Measure	Time frame
Visual analogue scales(VAS) score;	—

Countries

China

Contacts

Public ContactFeng Tao

Beijing Tiantan Hospital, Capital Medical University

happyft@sina.com+86 13911125339

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026